Responses

Download PDFPDF

Images in…
Tracheal fistula associated with bevacizumab 20 months after mediastinal radiation
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    A response to the editorial blog on case-report: Tracheal fistula associated with bevacizumab 20 months after mediastinal radiation
    Historically, the use of novel treatments, sometimes still in clinical trials, has led to significant breakthroughs in the management of incurable conditions. Highly active antiretroviral therapy (HAART) for HIV is a success story of modern medicine. But in the not so distant past (1988), HIV patients faced with certain death, campaigned for the fast-tracking of public access for drugs still in clinical trials at an attempt to sa...
    Show More
    Conflict of Interest:
    None declared.